...
Interpreting Medical Literature
June 7, 2019

Featuring Dr. Jennie Clarke and Dr. Joslyn Kirby This morning Dr. Jennie Clarke and Dr. Joslyn Kirby gave a wonderful presentation reviewing pertinent medical literature from the last year applicable to current dermatology practice. Confirming what most in the dermatology field already believed, a recent JAMA Dermatology article revealed total unprotected sun exposure is significantly

...
Use of DPP-4 Inhibitors May Increase Risk of Developing Bullous Pemphigoid in Diabetic Patients
December 3, 2018

Dipeptidyl-Peptidase 4 Inhibitors (DPP-4), belong to a class of anti-hyperglycemic agents indicated for improving glycemic control in patients with type-2 diabetes. As their use has increased, so has the number of cases of Bullous Pemphigoid (BP), a chronic skin disorder characterized by blisters, hives and itching. A recent study used a case-control method to answer

...
Doxycycline or Prednisolone? Which Is Better to Treat Bullous Pemphigoid
March 5, 2018

Bullous pemphigoid (BP) is a relatively rare blistering skin disorder that causes intense itching, erythema, blisters and risk for secondary infection, mostly affecting patients older than 70. A recent clinical trial, The Bullous Pemphigoid Steroids and Tetracyclines (BLISTER), compared strategies of starting treatment with doxycycline or with oral prednisolone. The goals were to determine whether